SCHEMBL4823733

SCHEMBL4823733

CNc1ccccc1SCc1cc(Br)ccc1OC

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MC4R P32245 5/20 0.42
TDP1 Q9NUW8 2/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
THRB P10828 1/20 0.41
ALOX15 P16050 1/20 0.41
CASP1 P29466 1/20 0.41
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8495432 0.84 METAP2 (0.47) KDM4EALDH1A1SMN1; SMN2MAPTL3MBTL1
SCHEMBL4360177 0.83 KMT2A (0.45) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4823936 0.82 KDM4E (0.47) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4007811 0.81 KDM4E (0.46) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL18920757 0.81 KDM4E (0.46) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL4823620 0.80 ALDH1A1 (0.45) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4160348 0.79 SLC6A4 (0.55) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4821326 0.78 SMN1; SMN2 (0.43) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4161772 0.77 CCR5 (0.45) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL6745160 0.77 ALDH1A1 (0.54) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-6699873-B1 EATING DISORDERS MILLENNIUM PHARMACEUTICALS, INC. 2004-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof MC4R, MC5R, MC3R MEN1 320/4885KMT2A 1838/4885KDM4E 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.